Literature DB >> 16510474

MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.

Andy C Parrott1.   

Abstract

Many recreational ecstasy/MDMA users display neuropsychobiological deficits, whereas others remain problem free. This review will investigate some of the drug and non-drug factors which influence the occurrence of these deficits. Acute and chronic MDMA usage are both important. Intensive use within a session is often associated with more problems. In term of lifetime usage, novice users generally remain unimpaired, whereas most heavy users report memory or other psychobiological problems which they attribute to ecstasy. These complaints are confirmed by objective deficits in working memory, attention, frontal-executive, and episodic memory tasks. Psychobiological deficits include disturbed sleep, sexual dysfunction, reduced immuno-competence, and increased oxidative stress. Further MDMA-related factors which may contribute to these changes, include acute and chronic tolerance, and drug dependence. Around 90ñ95% of ecstasy/MDMA users also take cannabis, and this can independently contribute to the adverse neuropsychobiological pro.les; although in some situations the acute co-use of these two drugs may be interactive rather than additive, since cannabis has relaxant and hypothermic properties. Alcohol, nicotine, amphetamine, and other drugs, can also affect the psychobiological pro.les of ecstasy polydrug users in complex ways. Pure MDMA users are rare but they have been shown to display significant neurocognitive deficits. Psychiatric aspects are debated in the context of the diathesis-stress model. Here the stressor of ecstasy polydrug drug use, interacts with various predisposition factors (genetic, neurochemical, personality), to determine the psychiatric outcome. Recreational MDMA is typically taken in hot and crowded dances/raves. Prolonged dancing, feeling hot, and raised body temperature, can also be associated with more psychobiological problems. This is consistent with the animal literature, where high ambient temperature and other metabolic stimulants boost the acute effects of MDMA, and cause greater serotonergic neurotoxicity. In conclusion, the neuropsychobiological effects of MDMA are modulated by a wide range of drug and non-drug factors. These multiple influences are integrated within a bioenergetic stress model, where factors which heighten acute metabolic distress lead to more neuropsychobiological problems.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16510474     DOI: 10.1177/0269881106063268

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  39 in total

1.  MDMA and 5-HT neurotoxicity: the empirical evidence for its adverse effects in humans - no need for translation.

Authors:  Andrew C Parrott
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

2.  Basal functioning of the hypothalamic-pituitary-adrenal (HPA) axis and psychological distress in recreational ecstasy polydrug users.

Authors:  Mark A Wetherell; Catharine Montgomery
Journal:  Psychopharmacology (Berl)       Date:  2013-11-05       Impact factor: 4.530

3.  Equivalent effects of acute tryptophan depletion on REM sleep in ecstasy users and controls.

Authors:  Robin L Carhart-Harris; David J Nutt; Marcus R Munafo; David M Christmas; Sue J Wilson
Journal:  Psychopharmacology (Berl)       Date:  2009-07-08       Impact factor: 4.530

4.  Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy.

Authors:  Lynn T Singer; Derek G Moore; Sarah Fulton; Julia Goodwin; John J D Turner; Meeyoung O Min; Andrew C Parrott
Journal:  Neurotoxicol Teratol       Date:  2012-03-03       Impact factor: 3.763

Review 5.  Altered energy production, lowered antioxidant potential, and inflammatory processes mediate CNS damage associated with abuse of the psychostimulants MDMA and methamphetamine.

Authors:  Luke A Downey; Jennifer M Loftis
Journal:  Eur J Pharmacol       Date:  2014-01-28       Impact factor: 4.432

6.  Psychiatric profiles of mothers who take Ecstasy/MDMA during pregnancy: reduced depression 1 year after giving birth and quitting Ecstasy.

Authors:  John J D Turner; Andrew C Parrott; Julia Goodwin; Derek G Moore; Sarah Fulton; Meeyoung O Min; Lynn T Singer
Journal:  J Psychopharmacol       Date:  2013-12-10       Impact factor: 4.153

7.  One-year outcomes of prenatal exposure to MDMA and other recreational drugs.

Authors:  Lynn T Singer; Derek G Moore; Meeyoung O Min; Julia Goodwin; John J D Turner; Sarah Fulton; Andrew C Parrott
Journal:  Pediatrics       Date:  2012-08-20       Impact factor: 7.124

Review 8.  Neuropathology of substance use disorders.

Authors:  Jean Lud Cadet; Veronica Bisagno; Christopher Mark Milroy
Journal:  Acta Neuropathol       Date:  2013-11-29       Impact factor: 17.088

9.  During pregnancy, recreational drug-using women stop taking ecstasy (3,4-methylenedioxy-N-methylamphetamine) and reduce alcohol consumption, but continue to smoke tobacco and cannabis: initial findings from the Development and Infancy Study.

Authors:  Derek G Moore; John D Turner; Andrew C Parrott; Julia E Goodwin; Sarah E Fulton; Meeyoung O Min; Helen C Fox; Fleur M B Braddick; Emma L Axelsson; Stephanie Lynch; Helena Ribeiro; Caroline J Frostick; Lynn T Singer
Journal:  J Psychopharmacol       Date:  2009-11-25       Impact factor: 4.153

10.  Auditory event-related potentials (P3) and cognitive performance in recreational ecstasy polydrug users: evidence from a 12-month longitudinal study.

Authors:  Susana de Sola; Thais Tarancón; Jordi Peña-Casanova; Josep María Espadaler; Klaus Langohr; Sandra Poudevida; Magí Farré; Antonio Verdejo-García; Rafael de la Torre
Journal:  Psychopharmacology (Berl)       Date:  2008-06-26       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.